


Consider entry into clinical trials for all eligible patients


Chemotherapy Algorithm for Classical Hodgkin Lymphoma



Version: 2	Approved by Chair of Haematology Tumour Group:
Reason for Update: reflects dropping of bleomycin in ABVD if PET/CT-ve; Brentuximab NICE approved; Nivolumab, GDP and BEACOPP-14 added	
Prepared by: S Taylor	Date: 27.11.17

Consider entry into clinical trials for all eligible patients

Chemotherapy Algorithm for Nodular Lymphocyte predominant Hodgkin Lymphoma



Version: 2	Approved by Chair of Haematology Tumour Group:
Reason for Update: reflects dropping of bleomycin in ABVD if PET/CT-ve; Brentuximab NICE approved; Nivolumab, GDP and BEACOPP-14 added	
Prepared by: S Taylor	Date: 27.11.17